Acute Coronary Syndrome
Evaluate the Effects of DalcetrapibDalcetrapib is a CETP inhibitor which was being developed by Hoffmann–La Roche until May 2012 on Cardiovascular (CV) Risk in a Genetically Defined Population With a Recent Acute Coronary Syndrome (ACS)Acute Coronary Syndrome.
CRITERIA LIST/ QUALIFICATIONS:
- Subjects recently hospitalized for ACS (between 4 and 12 weeks following the index event).
- AA genotype at variant gene as determined by Genotype Assay testing.
- Clinically stable, ie, free of ischemic symptoms at rest or with minimal exertion for at least 1 week prior to randomization.
Thomas Knickelbine, MD